[ad_1]
The US stock market hasn’t been particularly bearish recently, but it has fallen sharply, which is a warning sign. Along with the resurgence of the European epidemic, some cities may be closed again. Now is the peak flu season in the fall and winter, and the global epidemic has entered a severe time. The preventive mindset has caused global stock markets to sell under pressure.
Wang Rongxu, analyst at Wanbao Investment Consulting, mentioned in the 9/22 column “If the market enters the correction, this group can take over” mentioned that the momentum of electronic weakness is insufficient and the market trend tends to to be organized. The biotech group, which has been reorganized for almost three months, has a chance to move up.
Peak Flu Season to the Sound of Biotech Rise
On September 24, the market soared and fell 319 points, falling below the quarterly line. Not all actions were saved. The drop often shot up 2% to 3%, but the OTC biotech index only fell 0.58%. Shares of biotech Wang Heyi (4743-TW) broke the trend and soared 2.8%. Yanuofa (4133-TW) and Sinochem (1762-TW) even closed at their daily limit, which is not easy. Are biotech stocks generating a second wave of market surges as of May through June?
Wang Rongxu, an analyst at Wanbao Investment Consulting, noted that foreign investors sold Taiwan shares for six consecutive days, totaling more than 82 billion yuan, averaging more than 10 billion yuan per day. It is inevitable that the market will back down. When entering the market to seek opportunities to make money, relatively defensive stocks are often market leaders. Not only does biotechnology have defensive characteristics, but the mid-autumn period to cool down is now approaching, and we must be vigilant about what will happen with the flu and corona pneumonia.
In addition, the share price of Julong textile stock (1466-TW) has soared by more than 50% since September. The main reason is that the original production of nylon yarn as a textile raw material has suffered losses for five consecutive quarters. After cutting back on hood production this year, shipments started in July and orders were issued in August. The monthly EPS reached 0.23 yuan, successfully turning a loss into a profit.
Wang Rongxu, an analyst at Wanbao Investment Consulting, said that as the flu season approaches, demand for test products is expected to increase substantially because the symptoms are the same as those of new coronary pneumonia. In June, Yanuofa (4133-TW), whose products were approved for listing by the new crown test, benefited from product shipments in July and August, and its revenue reached a new record for two months . September’s performance is also expected to challenge the peak. Recently, Yanuofa has also entered the development of the new corona vaccine, although it is still in the animal testing stage, the subject is rich, and the share price has risen sharply.
Taikangsheng, Sinochem, Baoling Investment Co., Ltd.
Taikang Biotech (6589-TW) is also a biotech stock with two topics of new crown and vaccine tests. Since September, he has quietly bought close to 3,000 copies. Taikang Biotechnology and Baoling (1760-TW) developed a rapid detection of new coronary pneumonia, which has been approved for listing in Taiwan. Japan and India have also submitted applications. If they pass customs, the performance will be a big boost.
Furthermore, Taikang Biotech has also cooperated with the high-end (6547-TW) to develop a new corona vaccine, which has now entered a phase I clinical trial in humans. American high-end vaccine manufacturer Moderna is the only licensed manufacturer of new corona vaccine technology at the US National Institutes of Health. The potential effect is good. The stock price has been in order over a period of time and it is worth following the market outlook.
Wang Rongxu, an analyst at Wanbao Investment Consulting, said the investment trust rarely buys super biotech stocks. As well as recently buying super Taikang Biotech (6589-TW) and Baoling (1760-TW), Sinochem (1762-TW) has also been favored. , Pushed the Sinochem 9/24 share price to a new high against the trend. There are also some electronic and transfer products that are also weathering the decline of this wave. More potential stock analysis will be shared with readers of Line’s fan group https://line.me/ti/p/@marbo888.
Join Wang Rongxu fan group for free now and share more information.
YouTube channel of Wang Rongxu, Chief Investor
https://www.youtube.com/channel/UCi-2okN64tcrY5F09E2pb1Q
Wang Rongxu, Chief Investment Officer Shopmaster FB Fan Group
http://bit.ly/2KGYiSg
Wang Rongxu, Chief Investor, Telegram Fan Group
https://t.me/marbo888
The company and the individual values recommended and analyzed
No inappropriate financial interest ratio Past performance does not guarantee future benefits
Investors must make independent judgments, prudential assessments and their own investment risks.
[ad_2]
